Vaccination Against Fungal Diseases: Lessons from Candida albicans (original) (raw)
Related papers
Difficult but Not Impossible: in Search of an Anti-Candida Vaccine
Current Tropical Medicine Reports, 2019
Purpose of Review Pervasive fungal infection among the immunocompromised population, in conjunction with a lack of effective treatment options, has demanded further scrutiny. Millions of people are still dying annually from fungal infections. While existing treatment for these fungal infections exists, it is difficult to administer without adverse effects in the immunocompromised and is slowly becoming obsolete due to varying mutation rates and rising resistance in multiple species. Thus, vaccines may be a viable target for preventing and treating fungal infections and addressing the critical challenge of such infections. Recent Findings Candida albicans, along with other non-albicans Candida species, is among the more virulent class of fungal specimens considered for vaccine development. C. albicans is responsible for a large percentage of invasive fungal infections among immunocompromised and immunocompetent populations and carries a relatively high mortality rate. In the last dec...
Vaccines against candidiasis: Status, challenges and emerging opportunity
Frontiers in Cellular and Infection Microbiology
Candidiasis is a mycosis caused by opportunistic Candida species. The occurrence of fungal infections has considerably increased in the last few years primarily due to an increase in the number of immune-suppressed individuals. Alarming bloodstream infections due to Candida sp. are associated with a higher rate of morbidity and mortality, and are emerged as major healthcare concerns worldwide. Currently, chemotherapy is the sole available option for combating fungal diseases. Moreover, the emergence of resistance to these limited available anti-fungal drugs has further accentuated the concern and highlighted the need for early detection of fungal infections, identification of novel antifungal drug targets, and development of effective therapeutics and prophylactics. Thus, there is an increasing interest in developing safe and potent immune-based therapeutics to tackle fungal diseases. In this context, vaccine design and its development have a priority. Nonetheless, despite significa...
Vaccines for fungal infections
The National medical journal of India
High morbidity and mortality caused by mycotic infections has been a cause for concern. Trials for various vaccines against fungal pathogens have not been approved by the US Food and Drugs Administration because of the high cost of production and lack of a single suitable candidate. Most fungal infections require cell-mediated immunity for their clearance. This has been the basis for the development of various vaccines. We discuss the various trials of candidate vaccines, the protective efficacy as well as their shortcomings. Recent research suggests that a universal vaccine can be prepared which may be effective against most fungal pathogens.
Prospects for the development of fungal vaccines
Clinical microbiology reviews, 1997
In an era that emphasizes the term "cost-effective," vaccines are the ideal solution to preventing disease at a relatively low cost to society. Much of the previous emphasis has been on childhood scourges such as measles, mumps, rubella, poliomyelitis, and Haemophilus influenzae type b. The concept of vaccines for fungal diseases has had less impact because of the perceived limited problem. However, fungal diseases have become increasingly appreciated as serious medical problems that require recognition and aggressive management. The escalation in the incidence and prevalence of infection has prompted a renewed interest in vaccine development. Herein, I discuss the most recent developments in the search for vaccines to combat fungal infections. Investigators have discovered several inert substances from various fungi that can mediate protection in animal models. The next challenge will be to find the suitable mode of delivery for these immunogens.
2021
Candidiasis can be in various forms, the most dangerous of them are systemic and visceral candidiases. Many researchers believe that using drugs that are able to stimulate a protective immune response against candidal infections, i.e. immunobiological drugs, is a promising direction in the fight against candidiasis, and that these drugs are an alternative to antifungal agents. The aim of the work was to compare the therapeutic properties of the inactivated and subunit vaccines of cells of C. albicans and C. tropicalis fungi. Previously, animals were infected with the candidal infection. In 5 days, after infection the vaccines studied were injected to mice intramuscularly in the volume of 0.2 ml in the upper part of the rear right paw. In 14 days, these vaccines were injected to mice in the volume of 0.2 ml in the upper part of the rear left paw. In 14 days, the body protection functions were determined by the titer of C. albicans specific antibodies when performing the enzyme-linked...